Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: A review from the southern network on adverse reactions (SONAR)

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 759-767

  Maxwell, Whitney D ^a   Bennett, Charles L ^a,b,c,d  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d WJB Dorn VA Medical Center   (United States)

Author keywords

anticoagulants; cancer; chemotherapy; thromboprophylaxis; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BEVACIZUMAB; CERTOPARIN; CISPLATIN; CLOPIDOGREL; D DIMER; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FIBRIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; SEMULOPARIN; THALIDOMIDE; WARFARIN;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL RESEARCH; COMORBIDITY; DRUG INDUCED DISEASE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELOMA; OSTEOPOROSIS; PANCREAS CANCER; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AMBULATORY CARE; ANTINEOPLASTIC AGENTS; DRUG THERAPY; FIBRINOLYTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84868520460     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328893     Document Type: Review

References (47)

1. Streiff M. B., Bockenstedt P. L., Cataland S. R., et al. Venous thromboembolic disease. J Natl Compr Canc Netw: 2011; 9 7 714 777
2. Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost: 2007; 5 3 632 634 (Pubitemid 46680709)
3. Khorana A. A., Francis C. W., Culakova E., Fisher R. I., Kuderer N. M., Lyman G. H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol: 2006; 24 3 484 490 (Pubitemid 46630468)
4. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722 (Pubitemid 40216041)
5. Spencer F. A., Lessard D., Emery C., Reed G., Goldberg R. J. Venous thromboembolism in the outpatient setting. Arch Intern Med: 2007; 167 14 1471 1475 (Pubitemid 47124177)
6. Imberti D., Agnelli G., Ageno W., et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica: 2008; 93 2 273 278 (Pubitemid 351397716)
7. Chew H. K., Wun T., Harvey D., Zhou H., White R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med: 2006; 166 4 458 464
8. Lyman G. H., Khorana A. A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol: 2007; 25 34 5490 5505 (Pubitemid 350232226)
9. Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 10 4902 4907
10. Sood S. L. Cancer-associated thrombosis. Curr Opin Hematol: 2009; 16 5 378 385
11. Prandoni P., Lensing A. W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood: 2002; 100 10 3484 3488 (Pubitemid 35303914)
12. Moore R. A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 25 3466 3473
13. Otten H. M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med: 2004; 164 2 190 194 (Pubitemid 38140406)
14. Bennett C. L., Schumock G. T., Desai A. A., et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med: 2002; 113 7 603 606 (Pubitemid 35379916)
15. Bennett C. L., Angelotta C., Yarnold P. R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA: 2006; 296 21 2558 2560 (Pubitemid 44903859)
16. Deitcher S. R., Gomes M. P. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer: 2004; 101 3 439 449 (Pubitemid 38970595)
17. Bennett C. L., Silver S. M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: 2008; 299 8 914 924 (Pubitemid 351397066)
18. Nalluri S. R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: 2008; 300 19 2277 2285
19. Hurwitz H. I., Saltz L. B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol: 2011; 29 13 1757 1764
20. den Exter P. L., Hooijer J., Dekkers O. M., Huisman M. V. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol: 2011; 29 17 2405 2409
21. Di Nisio M., Ferrante N., De Tursi M., et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost: 2010; 104 5 1049 1054
22. Dentali F., Ageno W., Becattini C., et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res: 2010; 125 6 518 522
23. Browne A. M., Cronin C. G., English C., Ni Mhuircheartaigh J., Murphy J. M., Bruzzi J. F. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol: 2010; 5 6 798 803
24. Kahn S. R., Lim W., Dunn A. S., et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 Suppl e195S e226S
25. Gould M. K., Garcia D. A., Wren S. M., et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 Suppl e227S e277S
26. Mandalà M., Falanga A., Roila F. ESMO Guidelines Working Group Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol: 2011; 22 06 vi85 vi92
27. Wright J. D., Lewin S. N., Shah M., et al. Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. Ann Surg: 2011; 253 6 1140 1146
28. Abdel-Razeq H., Albadainah F., Hijjawi S., Mansour A., Treish I. Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax! J Thromb Thrombolysis: 2011; 31 1 107 112
29. Kucher N., Spirk D., Baumgartner I., et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol: 2010; 21 5 931 935
30. Trujillo-Santos J., Nieto J. A., Ruíz-Gamietea A., et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res: 2010; 125 02 S58 S61
31. Garcia D. A., Baglin T. P., Weitz J. I., Samama M. M. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 Suppl e24S e43S
32. Ay C., Dunkler D., Marosi C., et al. Prediction of venous thromboembolism in cancer patients. Blood: 2010; 116 24 5377 5382
33. Ay C., Dunkler D., Simanek R., et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol: 2011; 29 15 2099 2103
34. Geerts W. H., Bergqvist D., Pineo G. F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest: 2008; 133 6 Suppl 381S 453S (Pubitemid 351894916)
35. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet: 1994; 343 8902 886 889 (Pubitemid 24113632)
36. Palumbo A., Cavo M., Bringhen S., et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol: 2011; 29 8 986 993
37. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc: 2005; 80 12 1568 1574 (Pubitemid 41747058)
38. Maraveyas A., Waters J., Roy R., et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer: 2012; 48 9 1283 1292
39. Perry J. R., Julian J. A., Laperriere N. J., et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost: 2010; 8 9 1959 1965
40. Agnelli G., Gussoni G., Bianchini C., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol: 2009; 10 10 943 949
41. Agnelli G., George D. J., Kakkar A. K., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med: 2012; 366 7 601 609
42. Haas S. K., Freund M., Heigener D., et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost: 2012; 18 2 159 165
43. Lebeau B., Chastang C., Brechot J. M., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Celluleso" Group. Cancer: 1994; 74 1 38 45 (Pubitemid 24187607)
44. Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost: 2004; 2 8 1266 1271 (Pubitemid 40186120)
45. Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol: 2004; 22 10 1944 1948 (Pubitemid 41095187)
46. Sideras K., Schaefer P. L., Okuno S. H., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc: 2006; 81 6 758 767 (Pubitemid 43839491)
47. Akl E. A., Schünemann H. J. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med: 2012; 366 7 661 662